Versartis Inc, (Nasdaq: VSAR) Moves Higher

Versartis, Inc – OTCQB: VSAR

Shares of Versartis, Inc. are moving higher in early trading on heavy volume. The Menlo, CA-based company trades on the Nasdaq under ticker symbol VSAR. Versartis is an endocrine-focused biopharmaceutical company that is developing a form of recombinant human growth hormone to treat growth hormone deficiency (GHD) in children and adults.

Unconfirmed reports suggest that Versartis, Inc has filed a “Confidential Treatment Report” with the SEC. Such a filing would allow for information in an SEC filing to be kept secret, if leaking such information could cause material or financial harm to the company or a business partner.

Shares of VSAR closed yesterday at $13.30 and are trading at $15.10 at 11:22 EST. Volumes are heavy and trader chat rooms are active. According to information gathered from the Nasdaq website, four firms follow VSAR – one rating it as a “Hold” and three giving it a “Strong Buy”. The consensus price target is $23.50.

Always perform your own due diligence before making any decisions regarding the buy or sale of any stock. All information or data is provided without any guarantee of its accuracy.

Ticker Symbol VSAR
Last Price a/o 11:27 EST  $             14.85
Average Volume 181,260
Market Cap $469.89
Shares Outstanding 35.33 million
Share Float 34.57 million
Shortable Yes
Optionable Yes
Inside Ownership 0.90%
Short Float 2.43%
Short Interest Ratio 4.64
Quarterly Return 3.22%
YTD Return 7.34%
Year Return 11.30%


Author: Steve Clark

Steve Clark is a 23 year Wall St professional with stints in M&A, risk management, and algorithm trading.

Leave a Reply

Your email address will not be published. Required fields are marked *